Radium-223 dichloride (BAY88-8223)

DRUG6 trials

Conditions

Bone MetastasesHormone Refractory Prostate CancerNeoplasm MetastasisProstate CancerProstatic Neoplasms

Phase 1

Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases

CompletedNCT01798108

BayerNeoplasm Metastasis

Start: 2001-08-14End: 2003-06-25Updated: 2017-05-19

Phase 2

BAY88-8223, Dose Finding Study in Patients With HRPC

CompletedNCT00337155

BayerNeoplasm Metastasis, Prostate Cancer

Start: 2006-05-31End: 2009-12-31Updated: 2023-11-02

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

CompletedNCT00459654

BayerNeoplasm Metastasis, Prostate Cancer

Start: 2004-02-29End: 2007-05-31Updated: 2014-06-25

BAY88-8223, Does Response Study in HRPC Patients

CompletedNCT00667199

BayerBone Metastases, Hormone Refractory Prostate Cancer

Start: 2005-05-30End: 2009-10-06Updated: 2023-04-19

Phase 3

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

CompletedNCT01618370

BayerProstatic Neoplasms

Start: 2012-07-22End: 2016-02-28Updated: 2017-03-31

Unknown Phase

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

NCT01516762

BayerProstatic Neoplasms

Updated: 2014-07-14

BMC Cancer2019-01-0751 citations

Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology2018-10-017 citations

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

2017-11-2851 citations

Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).

Journal of Clinical Oncology2017-02-204 citations

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

2016-07-26193 citations

Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).

Journal of Clinical Oncology2016-05-2027 citations

Effect of radium-223 dichloride (Ra-223) on pain from US EAP.

Journal of Clinical Oncology2015-05-203 citations

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

Journal of Clinical Oncology2015-03-0118 citations

Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.

Journal of Clinical Oncology2015-03-0112 citations

Effect of radium-223 dichloride (Ra-223) on pain from US EAP.

Journal of Clinical Oncology2015-03-018 citations

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

2012-09-13113 citations